A study on prostate cancer bone metastasis identified FN1 as a key player in macrophage-induced anti-androgen resistance, proposing the FN1-integrin-SRC signaling axis as a potential therapeutic target for metastatic castration-resistant prostate cancer [41]. Here, SRC is linked to prostate carcinoma.